SEC Form 4 · accession 0001424422-16-000029
BioPharmX Corp · BPMX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephen Morlock
Director
Period of report
Jul 21, 2016
Accepted (ET)
Jul 25, 2016 · 7:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001504167
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to purchase common stockF1,F2 | $0.62 | Jul 21, 2016 | A | 65,000 | A | Aug 21, 2016 | Jul 21, 2026 | Common stock | 65,000 | 175,000 | I |
Explanation of responses
- F1This option vests ratably over 12 months with the first vesting starting on 8/21/16.
- F2Mr. Morlock is a co-trustee and co-beneficiary of the Stephen W. Morlock and Karen R. Morlock TTE UDT dated 04/21/03